The Patient-Centric Clinical Supply Chain For Cell And Gene Therapies

By Fiona Geiger, Vice President of Client Services, Yourway

Cell and gene therapies present a new frontier in targeted, patient-centric treatments for a wide range of rare diseases that have not been well addressed by more conventional therapies. However, owing to the unique supply chains — particularly for autologous cell therapies — strict temperature controls and short viability windows of these products, delivering these therapies to patients requires new levels of agility, flexibility and innovation in the logistical management of supply.